Quality of Life Comparison in Advanced Non-squamous Non Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Cisplatin and pemetrexed combination or carboplatin, paclitaxel and bevacizumab are now
considered as standard treatment in non-squamous cell lung carcinoma (NSCLC). Both main
registrative trials are considered positive because they reached their objectives, but within
them, the Quality of Life (QoL) of patients was not detailed neither has represented as
primary objective of the studies. It is considered that, together with enhancements that are
added to the knowledge of the biology of NSCLC, QoL may influence the therapeutic choice if
one of the associations show to be better tolerated by the patient and favours an
amelioration of his QoL.